asciminib

CALGARY, Alberta, Dec. 10, 2025 — Hemostemix Inc., a leader in autologous stem cell therapeutics, announced two pivotal corporate...

MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement...